RPS6KA3 and neoplasm: Expression of ISG15 was linked to resistance to cisplatin treatment in tumor cells, suggesting ISG15 is a biomarker for drug sensitivity (Huo et al., 2017; Wang et al., 2020) which is consistent with our data showing increased ISG15 and induced cisplatin sensitivity in RSK2 knockout cells.